Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: The GLISTEN study - A randomised controlled trial

  • P.A. Frith
  • , Philip Thompson
  • , R. Ratnavadivel
  • , C.L. Chang
  • , P. Bremner
  • , P. Day
  • , C. Frenzel
  • , N. Kurstjens
  • , A. Waddell
  • , A. Daniel
  • , A. Khoussousi
  • , A. Springfield
  • , A. Veale
  • , A.N. Graham
  • , B. Gallagher
  • , B.R. Pande
  • , B. O'Kane
  • , C. Jones
  • , C. Baldi
  • , C. Helm
    • C. O'Dochartaigh, D. Chambers, D. Quinn, D. Yull, D. Karthigesu, E. Then, F. Graham, F. Faigenbaum, G. Geddam, G. Cameron, H. Blom, H. Goldman, H. Snell, I. Chia, J. Jeong, J. Liew, J. Salvaris, J. Pryke, J. Reid, J. Kolbe, J. O'Sullivan, J. Pak, J. Upham, J. Feiber, J.O.M. Ford, K. Yong, K. Perrin, L. Noonan, L. Atlas, L. Murdoch, M. Pearce, M. Bloch, M. Holmes, M. Chia, M. Epton, M. Leadston, M.K. Tandon, M. Chitgopeker, N. Liebenberg, N. Hendry, O. Olaniyi, O. Singh, P. Kendall, P. Van Niekerk, R. Willet, R. Tomlins, S. Pillay, S. Sharifeh, S. Carson, S. Bingham, T. Walford, T. Erasmus, T. Claridge, Z. Hess

    Research output: Contribution to journal › Article › peer-review

    86 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: The GLISTEN study - A randomised controlled trial'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science